Free Trial
NASDAQ:AUTL

Autolus Therapeutics Q1 2025 Earnings Report

Autolus Therapeutics logo
$1.41 +0.10 (+7.63%)
As of 04/30/2025 04:00 PM Eastern

Autolus Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.24
Beat/Miss
N/A
One Year Ago EPS
N/A

Autolus Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.59 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Autolus Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Autolus Therapeutics Earnings Headlines

Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
See More Autolus Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Autolus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Autolus Therapeutics and other key companies, straight to your email.

About Autolus Therapeutics

Autolus Therapeutics (NASDAQ:AUTL), a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

View Autolus Therapeutics Profile

More Earnings Resources from MarketBeat